There is a global epidemic of psychiatric and neurological conditions with severe unmet needs and an opportunity for new and more effective treatments.1
Beckley Psytech is exploring how psychedelics can transform the treatment of neuropsychiatric conditions through its pipeline of investigational medicines.
By tailoring the therapeutic effects of these compounds through dose, delivery mechanism and personalised psychotherapy, Beckley Psytech aims to optimise treatment outcomes and reduce the burden on the patient, healthcare systems and society.
By enhancing the psychedelic treatment paradigm with digital tools to track, report and even predict patient outcomes, Beckley Psytech aims to redefine patient journeys, in order to deliver personalised treatment programmes that improve patient outcomes, reduce healthcare resource utilisation and bring meaningful change for patients.
By utilising AI-based technologies to research novel compositions of psychedelic compounds and new chemical entities, Beckley Psytech’s drug discovery engine, Beckley Deep Labs, is creating the next-generation of psychedelic-inspired medicines.
We are developing a pipeline of differentiated psychedelic products for psychiatric and neurological conditions:
Currently available medications are not effective for all people with depression. Treatment Resistant Depression (TRD) is the term used when two or more different antidepressant medicines have been ineffective and occurs in up to a third of people suffering with Major Depressive Disorder (MDD). TRD places a huge burden on the healthcare system. Our approach to psychedelic-assisted therapy targets clinically meaningful improvements in a less time- and resource-intensive psychotherapy session through the use of high potency, short acting psychedelic medicines.
Alcohol Use Disorder (AUD) is a medical condition characterised by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, alcohol addiction, and the colloquial term, alcoholism. AUD is a common and deadly condition. According to the Centre for Disease Control (CDC), more than 140,000 people die in the US from AUD every year1.Some people with alcohol use disorder who wish to abstain from or reduce alcohol consumption do not achieve their treatment goal with currently approved treatment options2. There remains a huge unmet medical need for these patients and an opportunity for new treatment approaches.